>
Freedom, Consciousness, Ethics, And AI – Derrick Broze at MIT
Starlink Completes "Successful" Military Test Deep In Arctic
FDA Approved, Controversial Lab-Grown Meat Becomes A Reality
Totalitarian Bid To Censor Entire Internet Behind Ireland Hate Speech Crackdown
Pentagon Scientists Discuss Cybernetic 'Super Soldiers' -
This TRANSPARENT ENGINE is Fascinating (How Engines Work) - Smarter Every Day 292
U.K. approves CRISPR gene editing to create GMO humans
Bigger and Better SpaceX Starship in a Few Months
'World's oldest languages' - that were carved into 5,000-year-old stones...
Google switches on first-of-its-kind advanced geothermal project
Designing A Self Propelling Ionic Thrust Wing
World's Smallest Nerf Gun Shoots an Ant
Nanoscale spinal implant helps restore mobility in paralyzed limbs
The exciting achievement came about after researchers were able to interfere with an enzyme typically found to be overactive in the brains of Alzheimer's patients.
The hyperactive enzyme, CDK5, was treated with an unnamed peptide, or string of amino acids.
Early tests conducted on mice revealed significant — and promising — results.
"This peptide has the ability to enter the brain and in a couple of different models, the peptide shows protective effects against loss of neurons and also appears to be able to rescue some of the behavior deficits," study author Li-Huei Tsai, director of MIT's Picower Institute for Learning and Memory, told The Post.
The hope, with further testing, is that this particular peptide might be a treatment for dementia — particularly dementia brought on by CDK5 overactivity.
The errant enzyme is triggered by a smaller protein called P35, which, in Alzheimer's patients, can become harmful when "cleaved" into a smaller protein known as P25 — which is also connected to Parkinson's disease.